Attendee search 

As a not-for-profit, the goal of One Million Solutions in Health is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 100's of new solutions and new scientific discoveries through the Technology Evaluation Consortium™ (contact us about membership). By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. As an example, we have had a fabulous, global response, through our sister company, to find cures and raise $100 million to support their commercialization.

We are thrilled to have you be a part of this transformative journey!

Our mission is to identify potential projects and participants across CUNY and in the community at large, to help members identify sources of funding and to prepare grant applications, to facilitate the execution of the projects, providing advice, space, and computer facilities, to create research programs by aggregating multiple projects with common defining factors (such programs will promote interactions and networking that will increase the value of the research activities with respect to the contribution of individual projects), to manage program projects with core competencies, and to establish collaborations outside CUNY (national and international)

We develop AZP2006 a first-in-class small molecule which modulates protein homeostasis. AZP2006 revolutionary mode of action has been shown to prevent Tau hyperphosphorylation and aggregation in vivo. Its nadditional neuroprotective properties allow to prevent both cognition and motor deficiencies induced by amyloid and other neurotoxics. AZP2006 will nter clinical phase 2 in 2016. It has obtained an orphan drug status for the treatment of PSP.

AZP2006 is developed for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease and Progressive Supranuclear Palsy.

Alzheimer's disease, Progressive supranuclear palsy, Frontotemporal dementia, Parkinson's disease

Innovative mode of action/ first-in-class candidate drug/ clinical phase / Orphan status

Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology –quiescent (sleeping) cancer cells. We are developing treatments and diagnostic assays to improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy resistant cancers: pancreatic, colorectal, non-small cell lung, and ovarian.

Recently, it has become accepted in the scientific community that populations of malignant cells are not homogenous, they have hierarchy.  Some of the cancer cells divide rapidly but some do not, some of the cancer cells are sleeping. They are in the quiescent state. This is especially true of solid tumors in which the cells in the outer layers are proliferating, but the inner volume comprises a large proportion of quiescent cells, frequently as a result of inadequate nutrient supply and oxygen deprivation (hypoxia). Hypoxic regions have long been known to be resistant to chemotherapy and radiation treatment. Tumor hypoxia, as a target for chemotherapy, is currently an active area of research.

Moreover, when cancer cells are under stress from either chemotherapy, anti-angiogenesis therapy, specific targeted treatment, or radiation, cancer cells often go to “sleep”, or use quiescent as a niche to hide.  After the completion of treatment, these cells can acquire resistance to the current treatment, begin growing and cause cancer recurrence. This process is called pharmacological quiescence.

The Private Company Access team leverages Citigroup’s strength and expertise in Institutional Sales and Trading to assist emerging growth companies with their investor relations objectives.
• Institutional investors are increasingly looking for access to emerging growth companies for direct investments, as well as to better understand looming risks to the public companies they own
• Growth-oriented companies are staying private longer, but need access to capital from institutional-type sources